Viatris Inc
Company Stats
- Market Cap
- $20.4B
- as of Sep 30, 2026
- Enterprise Value
- $33.0B
- Shares Outstanding
- 1.1B
- Free Float
- 99.6%
Income Statement
- Revenue
- $14.3B
- Operating Income
- -$2.7B
- Net Income
- -$3.5B
- EBITDA
- $135.2M
- Non-cash Impairment
- $2.9B
- Revenue Growth, 3Y
- -4.2%
- FCF Margin, 3Y Avg
- 14.5%
- FCF Margin, Worst Year
- 13.5%
Cash Flow
- Free Cash Flow
- $1.9B
- FCF Yield
- 9.5%
- Owner FCF Yield
- 8.6%
Balance Sheet
- Cash & Equivalents
- $1.3B
- Total Debt
- $14.0B
- Net Debt
- $12.7B
- Net Debt / EBITDA
- 93.60x
- EV / EBITDA
- 244.14x
Returns & Capital
- Share Repurchases
- $500.5M
- Buyback Yield, 3Y Avg
- 1.6%
- SBC, 3Y Avg
- $168.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $14.3B | $1.9B | 13.6% |
| FY2024 | $14.7B | $2.0B | 13.5% |
| FY2023 | $15.4B | $2.5B | 16.4% |
| FY2022 | $16.2B | $2.6B | 16.0% |
| FY2021 | $17.8B | $2.6B | 14.4% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 4, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 10, 2026
Weekly Deals
Schneider Electric signs $22.6 billion cash deal for PTC
October 8, 2026
Deals
Viatris to Buy Pacira BioSciences in $1.65 Billion Cash Deal
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Schneider Electric signs $22.6 billion cash deal for PTC
October 8, 2026
Deals
Viatris to Buy Pacira BioSciences in $1.65 Billion Cash Deal
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back